BRUKER CORPORATION (NASDAQ:BRKR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

0

BRUKER CORPORATION (NASDAQ:BRKR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On June 22, 2017, Mr. Chris van Ingen informed Bruker Corporation (the “Company”) of his intention to retire from the Company’s Board of Directors (the “Board”), including the Audit Committee and Nominating Committee, effective at the end of the day on June 30, 2017. Mr. van Ingen’s decision to retire from service as a director of the Company was for medical reasons and not related to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

The Company is deeply saddened to learn of Mr. van Ingen’s death on June 27, 2017. Mr. van Ingen served on the Company’s Board since 2012 and as a director of Bruker Energy & Supercon Technologies, Inc., a wholly-owned subsidiary of the Company, from 2009 to 2013. The Company’s Board and management are grateful for Mr. van Ingen’s guidance and leadership over the years and extend their deepest condolences to his family.

To fill the vacancies on Board committees created by Mr. van Ingen’s departure, the Board has appointed independent director Richard Packer to the Audit Committee and lead independent director William Linton to the Nominating Committee, in each case effective July 1, 2017. Additionally, the Board approved a reduction in the size of the Board from thirteen to twelve members, effective July 1, 2017, with each of the three Board classes to consist of four members.



About BRUKER CORPORATION (NASDAQ:BRKR)

Bruker Corporation is a designer and manufacturer of scientific instruments, and analytical and diagnostic solutions. The Company’s operating segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment. The Bruker BioSpin Group segment designs, manufactures and distributes enabling life science tools. The Bruker CALID segment designs, manufactures and distributes life science mass spectrometry instruments that can be integrated and used along with other sample preparation or chromatography instruments, as well as chemical, biological, radiological, nuclear and explosive (CBRNE) detection products. The Bruker Nano segment designs, manufactures and distributes spectroscopy and microscopy instruments. The BEST segment develops and manufactures superconducting and non-superconducting materials and devices.